Together with its well-documented roles in cancer, Gal3 has thus been considered as a potential therapeutic target to alleviate the fatal inflammation condition and subsequent lung fibrosis in COVID-19 patients, especially for those compromised with cancers. Here, LGALS3 is linked to pulmonary fibrosis.